FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022146334> ?p ?o ?g. }

• W2022146334 abstract "Lung adenocarcinoma patients with EGFR gene mutations have shown a dramatic response to gefitinib. However, drug resistance eventually emerges which limits the mean duration of response. With that in view, we examined the correlations between MET gene status as assessed by fluorescence in situ hybridization (FISH) with overall survival (OS) and progression-free survival (PFS) in adenocarcinoma patients with EGFR gene mutations who had received gefitinib therapy. We evaluated 35 lung cancer samples with EGFR mutation from adenocarcinoma patients who had received gefitinib. Gene copy numbers (GCNs) and amplification of MET gene before gefitinib therapy was examined by FISH. MET protein expression was also evaluated by immunohistochemistry (IHC). FISH assessment showed that of the 35 adenocarcinoma samples, 10 patients (29%) exhibited high polysomy (5 copies≦mean MET per cell) and 1 patient (3%) exhibited amplification (2≦MET gene (red)/CEP7q (green) per cell). IHC evaluation of MET protein expression could not confirm MET high polysomy status. The Eleven patients with MET FISH positivity had significantly shorter progression-free survival (PFS) and overall survival (OS) than the 24 patients who were MET FISH-negative (PFS: p = 0.001 and OS: p = 0.03). Median PFS and OS with MET FISH-positivity were 7.6 months and 16.8 months, respectively, whereas PFS and OS with MET FISH-negativity were 15.9 months and 33.0 months, respectively. Univariate analysis revealed that MET FISH-positivity was the most significant independent factor associated with a high risk of progression and death (hazard ratio, 3.83 (p = 0.0008) and 2.25 (p = 0.03), respectively). Using FISH analysis to detect high polysomy and amplification of MET gene may be useful in predicting shortened PFS and OS after Gefitinib treatment in lung adenocarcinoma. The correlation between MET gene status and clinical outcomes for EGFR-TKI should be further evaluated using large scale samples." @default.
• W2022146334 created "2016-06-24" @default.
• W2022146334 creator A5000338747 @default.
• W2022146334 creator A5011533142 @default.
• W2022146334 creator A5016933121 @default.
• W2022146334 creator A5026525537 @default.
• W2022146334 creator A5027883206 @default.
• W2022146334 creator A5034162457 @default.
• W2022146334 creator A5037262012 @default.
• W2022146334 creator A5045612681 @default.
• W2022146334 creator A5048704135 @default.
• W2022146334 creator A5054938771 @default.
• W2022146334 creator A5075238288 @default.
• W2022146334 creator A5083733013 @default.
• W2022146334 creator A5087511299 @default.
• W2022146334 creator A5087922163 @default.
• W2022146334 date "2015-02-06" @default.
• W2022146334 modified "2023-09-26" @default.
• W2022146334 title "MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation" @default.
• W2022146334 cites W1985264867 @default.
• W2022146334 cites W1987709860 @default.
• W2022146334 cites W1988442083 @default.
• W2022146334 cites W1989786382 @default.
• W2022146334 cites W1998971866 @default.
• W2022146334 cites W2003984225 @default.
• W2022146334 cites W2025288154 @default.
• W2022146334 cites W2043696829 @default.
• W2022146334 cites W2049937850 @default.
• W2022146334 cites W2055080028 @default.
• W2022146334 cites W2066128027 @default.
• W2022146334 cites W2106907092 @default.
• W2022146334 cites W2117454449 @default.
• W2022146334 cites W2129360604 @default.
• W2022146334 cites W2132157071 @default.
• W2022146334 cites W2140126391 @default.
• W2022146334 cites W2154402764 @default.
• W2022146334 cites W2160040938 @default.
• W2022146334 cites W2161821474 @default.
• W2022146334 cites W2219581640 @default.
• W2022146334 cites W285988926 @default.
• W2022146334 doi "https://doi.org/10.1186/s12885-015-1019-1" @default.
• W2022146334 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4437672" @default.
• W2022146334 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25886066" @default.
• W2022146334 hasPublicationYear "2015" @default.
• W2022146334 type Work @default.
• W2022146334 sameAs 2022146334 @default.
• W2022146334 citedByCount "29" @default.
• W2022146334 countsByYear W20221463342015 @default.
• W2022146334 countsByYear W20221463342016 @default.
• W2022146334 countsByYear W20221463342017 @default.
• W2022146334 countsByYear W20221463342018 @default.
• W2022146334 countsByYear W20221463342019 @default.
• W2022146334 countsByYear W20221463342020 @default.
• W2022146334 countsByYear W20221463342021 @default.
• W2022146334 countsByYear W20221463342022 @default.
• W2022146334 countsByYear W20221463342023 @default.
• W2022146334 crossrefType "journal-article" @default.
• W2022146334 hasAuthorship W2022146334A5000338747 @default.
• W2022146334 hasAuthorship W2022146334A5011533142 @default.
• W2022146334 hasAuthorship W2022146334A5016933121 @default.
• W2022146334 hasAuthorship W2022146334A5026525537 @default.
• W2022146334 hasAuthorship W2022146334A5027883206 @default.
• W2022146334 hasAuthorship W2022146334A5034162457 @default.
• W2022146334 hasAuthorship W2022146334A5037262012 @default.
• W2022146334 hasAuthorship W2022146334A5045612681 @default.
• W2022146334 hasAuthorship W2022146334A5048704135 @default.
• W2022146334 hasAuthorship W2022146334A5054938771 @default.
• W2022146334 hasAuthorship W2022146334A5075238288 @default.
• W2022146334 hasAuthorship W2022146334A5083733013 @default.
• W2022146334 hasAuthorship W2022146334A5087511299 @default.
• W2022146334 hasAuthorship W2022146334A5087922163 @default.
• W2022146334 hasBestOaLocation W20221463341 @default.
• W2022146334 hasConcept C104317684 @default.
• W2022146334 hasConcept C121608353 @default.
• W2022146334 hasConcept C126322002 @default.
• W2022146334 hasConcept C143998085 @default.
• W2022146334 hasConcept C204232928 @default.
• W2022146334 hasConcept C207103383 @default.
• W2022146334 hasConcept C2776256026 @default.
• W2022146334 hasConcept C2776694085 @default.
• W2022146334 hasConcept C2777542201 @default.
• W2022146334 hasConcept C2779438470 @default.
• W2022146334 hasConcept C2780580887 @default.
• W2022146334 hasConcept C2780739268 @default.
• W2022146334 hasConcept C2781182431 @default.
• W2022146334 hasConcept C2781303241 @default.
• W2022146334 hasConcept C30481170 @default.
• W2022146334 hasConcept C44249647 @default.
• W2022146334 hasConcept C54355233 @default.
• W2022146334 hasConcept C71924100 @default.
• W2022146334 hasConcept C86803240 @default.
• W2022146334 hasConceptScore W2022146334C104317684 @default.
• W2022146334 hasConceptScore W2022146334C121608353 @default.
• W2022146334 hasConceptScore W2022146334C126322002 @default.
• W2022146334 hasConceptScore W2022146334C143998085 @default.
• W2022146334 hasConceptScore W2022146334C204232928 @default.
• W2022146334 hasConceptScore W2022146334C207103383 @default.
• W2022146334 hasConceptScore W2022146334C2776256026 @default.
• W2022146334 hasConceptScore W2022146334C2776694085 @default.
• W2022146334 hasConceptScore W2022146334C2777542201 @default.

• next